We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche Acquires AbVitro Technology
News

Roche Acquires AbVitro Technology

Roche Acquires AbVitro Technology
News

Roche Acquires AbVitro Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Acquires AbVitro Technology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche obtained exclusive rights to a primer extension based target enrichment technology and associated patent applications filed by AbVitro.  Under the terms of the agreement, AbVitro and Roche scientists will collaborate on the development and application of the technology.

The primer extension based target enrichment (PETE) technology will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications. This PETE technology, will be incorporated into Roche’s Sequencing Unit R&D pipeline to support the strategy of providing a full next-generation sequencing workflow solution for clinical sequencing.

“The potential of this technology will allow Roche to optimize our sequencing portfolio to provide a full workflow solution for our customers,” said Dan Zabrowski, Head of Roche Tissue Diagnostics and the Sequencing Unit.  “Sequencing is transforming the understanding among researchers and clinicians of how genomics will impact health. We look forward to advancing this technology in order to streamline sequencing methods for easy-to-use clinical applications.”

“We are excited by Roche’s acquisition of our primer extension based target enrichment and the prospect of continued collaboration to develop the technology further. This technology surpasses current industry standards and we believe Roche to be incredibly well positioned to create a true disruption in the next-generation sample prep market,” said Dr. Francois Vigneault, President, CSO & Founder at AbVitro. “It is wonderful to see another potentially transformative sequencing technology transition into Roche where it can impact our daily lives,” said Dr. George Church, Professor of Genetics at Harvard Medical School, and Founder of AbVitro.

Advertisement